Top Medical News from Across Medscape

  • Few Endocrinologists Know Ertugliflozin Beyond Name: PollThe SGLT-2 type 2 diabetes drug is expected to get FDA approval by the end of the year. A Medscape poll finds that only 45% of endocrinologists had heard of it, and of those, 20% knew it only by name.
  • 'Exorbitant' Cost of SMA Drug Restricts Kids' AccessBioethicists and clinicians involved in the care of children with SMA are voicing concern over insurers' limiting reimbursement of nusinersen, which costs up to $750,000 a year.

Special Report

Business of Medicine

Medscape Editor-in-Chief

  • Eric J. Topol, MD Director, Scripps Translational Science Institute; Chief Academic Officer, Scripps Health; Professor of Genomics, The Scripps Research Institute, La Jolla, California